Battelle Secures Sole Award for DTRA STEP 2.0 Contract to Advance Global Biological Threat Reduction Initiatives Battelle, a global leader in scientific research and national security solutions, has been awarded the Defense Threat Reduction Agency’s (DTRA) Scientific and Technical Engagement…
Investor Consortium Backs Graforce’s Plasma Pyrolysis Technology to Revolutionize Low-Carbon Industrial Fuels A strategic investment consortium composed of Paris-based next-generation fuels industrial and technology fund Calderion (Audacity), infrastructure developer Terravent, and WenCo Family Office has officially closed a significant double-digit…
Gilead Sciences Presents Positive Phase 3 ARTISTRY Trial Data for Investigational Bictegravir/Lenacapavir HIV Regimen at CROI 2026 Gilead Sciences, Inc. today shared compelling new data from its Phase 3 ARTISTRY-1 and ARTISTRY-2 clinical trials at the 33rd Conference on Retroviruses…
ViiV Healthcare highlights promising investigational treatments designed to deliver long-acting HIV control with just two doses per year, aiming to improve adherence and patient convenience. ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi…
Montrose Environmental Group reports record revenue, earnings, and cash flow for 2025, driven by strong demand across core environmental solutions, and increases its 2026 guidance on continued operational momentum. Montrose Environmental Group, Inc. delivered a standout performance in 2025, reporting…
Agilent Technologies, Inc. reports 7% revenue growth to $1.80 billion, highlighting strong core performance and operational momentum in the first quarter of fiscal 2026. Agilent Technologies, Inc. (NYSE: A) reported a solid start to fiscal 2026, delivering first-quarter revenue of…
Thermo Fisher Scientific Announces 10% Increase in Cash Payout, Strengthening Commitment to Shareholder Returns and Long-Term Growth Thermo Fisher Scientific Inc , widely recognized as the world leader in serving science, has announced that its Board of Directors has authorized…
Aurinia Pharmaceuticals Inc. posts strong 2025 revenue growth and outlines strategic progress across its commercial and clinical pipeline. Aurinia Pharmaceuticals Inc. has reported strong financial and operational performance for the fourth quarter and full year ended December 31, 2025, highlighting…
Compass Pathways secures approximately $200 million in proceeds through the exercise of outstanding warrants, strengthening its balance sheet to advance psychedelic-based mental health therapies. Compass Pathways plc , a clinical-stage biotechnology company focused on transforming mental health care through evidence-based…
Backed by the Wyss Center for Bio and Neuroengineering and leading Swiss investors, Clee Medical advances ultra-high-resolution real-time imaging to enhance precision and safety in brain surgery. The Wyss Center for Bio and Neuroengineering in Geneva has announced the successful…